- Home
- PLCE vs SKYE Comparison
PLCE vs SKYE Comparison
Compare PLCE & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLCE
- SKYE
- Stock Information
- Founded
- PLCE 1969
- SKYE 2012
- Country
- PLCE United States
- SKYE United States
- Employees
- PLCE N/A
- SKYE N/A
- Industry
- PLCE Clothing/Shoe/Accessory Stores
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- PLCE Consumer Discretionary
- SKYE Health Care
- Exchange
- PLCE Nasdaq
- SKYE Nasdaq
- Market Cap
- PLCE 97.5M
- SKYE 101.3M
- IPO Year
- PLCE 1997
- SKYE N/A
- Fundamental
- Price
- PLCE $4.68
- SKYE $3.48
- Analyst Decision
- PLCE Hold
- SKYE Buy
- Analyst Count
- PLCE 1
- SKYE 7
- Target Price
- PLCE $6.00
- SKYE $15.50
- AVG Volume (30 Days)
- PLCE 432.8K
- SKYE 284.4K
- Earning Date
- PLCE 09-05-2025
- SKYE 08-07-2025
- Dividend Yield
- PLCE N/A
- SKYE N/A
- EPS Growth
- PLCE N/A
- SKYE N/A
- EPS
- PLCE N/A
- SKYE N/A
- Revenue
- PLCE $1,360,516,000.00
- SKYE N/A
- Revenue This Year
- PLCE N/A
- SKYE N/A
- Revenue Next Year
- PLCE $1.47
- SKYE N/A
- P/E Ratio
- PLCE N/A
- SKYE N/A
- Revenue Growth
- PLCE N/A
- SKYE N/A
- 52 Week Low
- PLCE $3.66
- SKYE $1.14
- 52 Week High
- PLCE $19.74
- SKYE $7.11
- Technical
- Relative Strength Index (RSI)
- PLCE 49.98
- SKYE 49.27
- Support Level
- PLCE $4.32
- SKYE $3.22
- Resistance Level
- PLCE $4.89
- SKYE $3.60
- Average True Range (ATR)
- PLCE 0.27
- SKYE 0.26
- MACD
- PLCE 0.04
- SKYE 0.01
- Stochastic Oscillator
- PLCE 65.71
- SKYE 65.82
About PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.